EC approves Pfizer’s Emblaveo for multidrug-resistant infections
23 Apr 2024
Drug ApprovalPhase 3
Preview
Source: Pharmaceutical Technology
The marketing approval is valid across all 27 member states in the EU. Credit: YES Market Media via Shutterstock.
The European Commission (EC) has granted marketing authorisation for Pfizer’s Emblaveo (aztreonam-avibactam), aimed at treating adults with multidrug-resistant infections where treatment options are limited.
This approval is a significant step in combating serious infections caused by aerobic Gram-negative organisms.
The authorisation covers the use of Emblaveo for complicated intra-abdominal infections, hospital-acquired and ventilator-associated pneumonia, as well as complicated urinary tract infections, including pyelonephritis.
Based on the positive outcomes from the Phase III REVISIT and ASSEMBLE clinical trials assessing the treatment’s efficacy, safety, and tolerability, the EC adopted the latest decision.
See Also:
FDA approves Utility Therapeutics’ Pivya tablets for UTIs
Preview
Source: Pharmaceutical Technology
Preview
Source: Pharmaceutical Technology
The latest marketing authorisation is valid across all 27 member states in the European Union (EU), including Iceland, Liechtenstein, and Norway.
Further submissions seeking approval for the treatment are planned for other countries.
Emblaveo has a combination of monobactam β-lactam, aztreonam, with avibactam, a new broad-spectrum β-lactamase inhibitorβ-lactamase inhibitor.
This combination revitalises the activity of aztreonam against bacteria that produces metallo-β-lactamases (MBLs) and other β-lactamases, offering a new solution for treating multidrug-resistant Gram-negative bacteria.
These bacteria include MBL-producing Enterobacterales and S. maltophilia, which is classified as a critical priority pathogen by the World Health Organization.
Emblaveo is the first β-lactam/β-lactamase inhibitorβ-lactamase inhibitor combination to receive approval in the EU for the treatment of serious bacterial infections in adults caused by multidrug-resistant Gram-negative bacteria, including those producing MBLs.
Pfizer chief international commercial officer and executive vice-president Alexandre de Germay said: “The European Medicines Agency’s accelerated review of Emblaveo reflects the urgent need for new treatments to address the threat of antimicrobial resistance.
“With this approval, Pfizer is proud to take another step forward in its commitment to developing and bringing breakthrough health solutions to patients impacted by serious infectious diseases around the world.”
Last month, the EC awarded marketing approval to Pfizer’s Prevenar 20 for the active immunisation and protection of infants and children against common pneumococcal diseases.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.